| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
( Division of Experimental Chemotherapy, The Sloan-Kettering Institute for Cancer Research, New York 21, N.Y.)
A nitrogen mustard, SK 1424, has been found which appears to be more efficient in retarding Sarcoma 180 than HN2, the nitrogen mustard used as our standard.
* We wish to acknowledge support of this study by funds from the American Cancer Society.
With the technical assistance of Margaret L. Keeve and Angela T. Boryczka.
Received 1/12/51.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |